BOLT vs CB · rev $7.7M vs P/E 14, rev $59.40B
Bolt Biotherapeutics (BOLT) versus Chubb Ltd (CB) — a side-by-side from cached financials, not a winner call.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
BOLT currently screens at market cap $11.3M. CB currently screens at market cap $114.26B and trailing P/E 13.7.
Not investment advice. Open the BOLT and CB stock pages for the full models.
Not investment advice.